

# Saverio Cinieri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5055155/saverio-cinieri-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96  
papers

2,897  
citations

26  
h-index

52  
g-index

102  
ext. papers

3,339  
ext. citations

4.9  
avg, IF

4.07  
L-index

#	Paper	IF	Citations
96	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 133-141	7.5	4
95	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINTenance Afinitor) trial. <i>European Journal of Cancer</i> , <b>2021</b> , 154, 21-29	7.5	1
94	Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). <i>Breast</i> , <b>2020</b> , 53, 18-22	3.6	5
93	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 178-186	7.5	23
92	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , <b>2019</b> , 133, 62-68	5.9	1
91	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 71	8.3	14
90	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 535-540	4.9	14
89	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , <b>2019</b> , 19, 283	4.8	8
88	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , <b>2019</b> , 132, 17-23	5.9	11
87	Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). <i>Breast</i> , <b>2019</b> , 45, 7-14	3.6	7
86	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 556-563	3.5	20
85	Pharmacotherapeutic options for patients with refractory breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 851-861	4	2
84	Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs. <i>Medical Oncology</i> , <b>2019</b> , 36, 80	3.7	6
83	A clinical evaluation of treatments that target cell cycle machinery in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 2305-2315	4	8
82	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , <b>2019</b> , 24, 385-393	5.7	15
81	Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE. <i>Oncologist</i> , <b>2019</b> , 24, e232-e240	5.7	8
80	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 591-597	3.6	4

79	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPIO study. <i>Future Oncology</i> , <b>2019</b> , 15, 33-44	3.6	11
78	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 474-485	21.7	39
77	An update on first line therapies for metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 243-252	4	5
76	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 127-138	21.7	62
75	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2585-2592 <sup>27</sup>	2.2	84
74	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). <i>Seminars in Oncology</i> , <b>2018</b> , 45, 259-263	5.5	2
73	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , <b>2018</b> , 18, 932	4.8	2
72	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1281-1287	2.2	84
71	Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'. <i>Future Oncology</i> , <b>2017</b> , 13, 971-978	3.6	12
70	Targeting triple negative breast cancer with histone deacetylase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 1199-1206	5.9	38
69	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3347-3353	2.2	45
68	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3001-3004	3.6	29
67	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i> , <b>2017</b> , 2, e000167	6	14
66	Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2017</b> , 17, 91-99.e1	3	9
65	Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. <i>Future Oncology</i> , <b>2017</b> , 13, 233-248	3.6	2
64	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. <i>Breast</i> , <b>2016</b> , 30, 151-155	3.6	23
63	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 100, 57-68	7	13
62	Response of extensive breast cancer skin metastases to rechallenge with trastuzumab together with low-dose chemotherapy and insulin. <i>Tumori</i> , <b>2016</b> , 102,	1.7	1

61	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2015</b> , 34, 10	12.8	50
60	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Study. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2015</b> , 34, 200-208	4.9	36
59	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 561-8	21.7	109
58	Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 67-70	4.9	12
57	Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience. <i>Tumori</i> , <b>2015</b> , 101, 524-8	1.7	4
56	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 155-62	5.4	26
55	Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2015</b> , 94, 291-301	7	19
54	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , <b>2015</b> , 193, 1905-10	2.5	9
53	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 166-70	4.9	24
52	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 396-405	21.7	271
51	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. <i>PLoS ONE</i> , <b>2014</b> , 9, e105268	3.7	25
50	BMI variation increases recurrence risk in women with early-stage breast cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 2459-68	3.6	16
49	Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. <i>Future Oncology</i> , <b>2014</b> , 10, 725-33	3.6	3
48	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. <i>Future Oncology</i> , <b>2014</b> , 10, 69-78	3.6	
47	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 501-6	4.7	7
46	Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?. <i>Medical Oncology</i> , <b>2013</b> , 30, 578	3.7	7
45	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2134-42	7.5	55
44	Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , <b>2013</b> , 17, 473-4	6.4	

43	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. <i>Lung Cancer</i> , <b>2013</b> , 81, 77-83	5.9	36
42	Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients. <i>Journal of Chemotherapy</i> , <b>2013</b> , 25, 369-75	2.3	2
41	Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. <i>PLoS ONE</i> , <b>2013</b> , 8, e74402	3.7	45
40	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , <b>2013</b> , 8, e83026	3.7	52
39	Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , <b>2013</b> , 99, 35-8	1.7	
38	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1830-1844	8.9	17
37	Second-line erlotinib for non-small-cell lung cancer. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e141-2; author reply e142	21.7	1
36	First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, 755-60	3.2	2
35	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3002-11	2.2	193
34	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16 Suppl 2, S111-7	6.4	12
33	Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 84, 243-51	7	45
32	MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. <i>Lung Cancer</i> , <b>2012</b> , 76, 373-9	5.9	21
31	Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16 Suppl 2, S83-9	6.4	6
30	Combined modality treatments in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16 Suppl 2, S71-81	6.4	9
29	Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review. <i>Tumori</i> , <b>2011</b> , 97, 690-692	1.7	13
28	Disparity in the time to patient access to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). <i>Tumori</i> , <b>2011</b> , 97, 442-448	1.7	4
27	Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE). <i>Clinical Lung Cancer</i> , <b>2011</b> , 12, 402-6	4.9	7
26	Genistein: the future of prevention and treatment of breast cancer?. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 11, 918-20	4.6	10

25	Fatherhood during imatinib. <i>Acta Oncologica</i> , <b>2011</b> , 50, 734-5	3.2	20
24	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , <b>2011</b> , 97, 690-2	1.7	11
23	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. <i>Lung Cancer</i> , <b>2010</b> , 69, 218-24	5.9	11
22	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 3, S87-94	14.4	31
21	Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies. <i>Breast</i> , <b>2010</b> , 19, 214-8	3.6	8
20	Rituximab in lymphocyte-predominant Hodgkin disease. <i>Oncology</i> , <b>2009</b> , 76, 26-9	3.6	11
19	Weekly epirubicin in the treatment of gestational breast cancer (GBC). <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 115, 591-4	4.4	53
18	Role of gemcitabine in metastatic breast cancer patients: a short review. <i>Breast</i> , <b>2008</b> , 17, 220-6	3.6	41
17	Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 370-8	2.2	58
16	Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 961-7	2.4	83
15	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: Case 2. Plasma cell myeloma coexisting with metastatic breast carcinoma in the bone marrow. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 232-3	2.2	4
14	Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.. <i>Blood</i> , <b>2005</b> , 106, 5401-5401	2.2	
13	Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. <i>Cancer Research</i> , <b>2004</b> , 64, 4373-7	10.1	80
12	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , <b>2004</b> , 72, 264-7	3.8	19
11	Toxoplasma gondii infection in patients with hematological malignancies. <i>Annals of Hematology</i> , <b>2004</b> , 83, 592-5	3	20
10	Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. <i>Cancer</i> , <b>2004</b> , 101, 1302-10	6.4	151
9	Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. <i>Clinical Breast Cancer</i> , <b>2004</b> , 5, 125-30	3	15
8	Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6039-46	12.9	17

7	REPLY TO GUNSILIUS ET AL. <i>British Journal of Haematology</i> , <b>2000</b> , 108, 662-663	4.5	
6	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 517-22	15.1	385
5	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>1999</b> , 106, 504-9	4.5	130
4	Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients. <i>Cancer Immunology, Immunotherapy</i> , <b>1994</b> , 38, 323-31	7.4	5
3	Biochemical and immunological responses of hairy cell leukemia patients to interferon beta. <i>Cancer Immunology, Immunotherapy</i> , <b>1991</b> , 34, 115-22	7.4	9
2	Electrophysiological and neuropsychological functions in patients treated with interferon-beta. <i>Journal of Interferon Research</i> , <b>1990</b> , 10, 613-9		12
1	Modulation of NK activity by thymic hormones: in vitro effects of thymostimulin. <i>Medical Oncology and Tumor Pharmacotherapy</i> , <b>1989</b> , 6, 45-52		4